title: Treatment and impact of dyslipidemia in diabetic nephropathy.
abstract: Recent epidemiological research revealed that dyslipidemia is a risk factor for development and progression of diabetic nephropathy. Results from interventional studies revealed the possibility that anti-hyperlipidemic agents have a better effect on diabetic nephropathy through improvement of albuminuria and loss of renal function. In addition, dyslipidemia may be a consequence of albuminuria and renal dysfunction, thereby perpetuating kidney damage. Today, the proportion of diabetic patients receiving statins is increasing due to their beneficial effect on cardiovascular mortality. However, treatment for patients should be determined based on consideration of the risk and benefit of the treatment. More insight into the pathogenesis of diabetic nephropathy and the effects of life-style changes is required.
authors.affiliation: Division of Nephrology, Kanazawa University Hospital, Kanazawa, Japan.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Toyama
authors.forename: Miho
authors.initials: M
authors.lastname: Shimizu
authors.forename: Kengo
authors.initials: K
authors.lastname: Furuichi
authors.forename: Shuichi
authors.initials: S
authors.lastname: Kaneko
authors.forename: Takashi
authors.initials: T
authors.lastname: Wada
mesh_terms: D000419:Albuminuria / Q000150:complications; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000150:complications*; D050171:Dyslipidemias / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D007668:Kidney / Q000503:physiopathology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors